Treatment of Recurrent or Metastatic Uterine Adenosarcoma.
Purpose. This study retrospectively evaluated overall survival (OS) by treatment of recurrent or metastatic uterine adenosarcoma including surgery, radiation, chemotherapy, and hormonal therapy and evaluated OS and progression-free survival (PFS) after 1st line systemic chemotherapy. Methods. 78 pat...
| Publicado en: | Sarcoma pp. 1 - 10 |
|---|---|
| Autores principales: | , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
12/28/2017
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=127006432&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 127006432 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 1357714X 57R jtl: Sarcoma issn: 1357714X maglogo: Y pubinfo: dt: 12/28/2017 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 127006432 127006432 127006432 10.1155/2017/4680273 127006432 ppf: 1 ppct: 9 formats: fmt: @attributes: type: P tig: atl: Treatment of Recurrent or Metastatic Uterine Adenosarcoma. aug: au: Nathenson, Michael J. Conley, Anthony P. Lin, Heather Fleming, Nicole Ravi, Vinod affil: Dana–Farber Cancer Institute, 450 Brookline Ave., Boston, MA 02215, USA sug: subj: Uterine Neoplasms Adenoma Sarcoma Neoplasm Metastasis Therapy Treatment Outcomes Human Retrospective Design Surgery, Operative Radiotherapy Chemotherapy, Cancer Hormone Therapy Kaplan-Meier Estimator Log-Rank Test Survival Disease Progression Doxorubicin Ifosfamide Gemcitabine Docetaxel ab: Purpose. This study retrospectively evaluated overall survival (OS) by treatment of recurrent or metastatic uterine adenosarcoma including surgery, radiation, chemotherapy, and hormonal therapy and evaluated OS and progression-free survival (PFS) after 1st line systemic chemotherapy. Methods. 78 patients with recurrent or metastatic adenosarcoma comprised the study population. The Kaplan-Meier method was used to estimate OS and PFS. The log-rank test was performed to test the difference in survival between groups. Results. Median OS from diagnosis of recurrent or metastatic disease was 1.8 yrs. OS was influenced by pathology on recurrence, p=0.035. Median OS differed by surgery for 1st recurrence 26.3 months versus 15.1 months. OS was not influenced by chemotherapy, p=0.58, palliative radiation, p=0.58, or hormonal therapy, p=0.15. The response rate (CR + PR) per RECIST 1.1 for chemotherapy was 31.2% for doxorubicin-based regimens and 14.3% for gemcitabine/docetaxel. OS since 1st line chemotherapy was not significantly different among chemotherapy regimens. However, the median PFS was superior for doxorubicin/ifosfamide (15.4 months) compared to gemcitabine/docetaxel (5.0 months), platinum-based regimens (5.7 mo), or other doxorubicin-based regimens (6.5 months). Conclusion. These results suggest that surgery is an important treatment modality for recurrent or metastatic uterine adenosarcoma, and the most effective chemotherapeutics are doxorubicin/ifosfamide and gemcitabine/docetaxel. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|